Literature DB >> 11106819

Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.

M A Nelson1, M D Radmacher, R Simon, M Aickin, J Yang, L Panda, J Emerson, D Roe, L Adair, F Thompson, J Bangert, S P Leong, R Taetle, S Salmon, J Trent.   

Abstract

We report the cytogenetic abnormalities from a series of 206 primary malignant melanoma specimens referred to a single institution. A total of 169 out of 206 unique cases had chromosome breakpoints. A previously described statistical method was used to detect nonrandom distribution of chromosome breakpoints at the level of chromosome regions. Nonrandom occurrence of chromosome breakpoints (indicating that the observed number of breaks significantly exceeded the expected number of breaks) was detected in 28 regions, suggesting a hierarchy of genetic abnormalities in melanoma. Clinical variables and tumor characteristics were analyzed for associations with the presence of any nonrandom chromosome breakpoints; with individual, nonrandomly involved chromosome regions; and with paired, nonrandomly involved chromosome regions. No nonrandomly involved chromosome regions or pairs of regions appeared to significantly affect survival. These results identify recurring, nonrandom chromosome abnormalities in malignant melanoma. These results suggest that recurring, nonrandom chromosome alterations play a key role in the etiology and/or progression of malignant melanoma and identify targets within the genome for molecular genetic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106819     DOI: 10.1016/s0165-4608(00)00281-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome.

Authors:  Heidi A Heilstedt; Blake C Ballif; Leslie A Howard; Richard A Lewis; Samuel Stal; Catherine D Kashork; Carlos A Bacino; Stuart K Shapira; Lisa G Shaffer
Journal:  Am J Hum Genet       Date:  2003-04-08       Impact factor: 11.025

2.  New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section.

Authors:  Meenhard Herlyn; Martin Padarathsingh; Lynda Chin; Mary Hendrix; Dorothea Becker; Mark Nelson; Yves DeClerck; James McCarthy; Suresh Mohla
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma.

Authors:  Ichiro Okamoto; Christine Pirker; Martin Bilban; Walter Berger; Doris Losert; Christine Marosi; Oskar A Haas; Klaus Wolff; Hubert Pehamberger
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

4.  Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Authors:  Maria Isabella Sereni; Elisa Baldelli; Guido Gambara; Antonella Ravaggi; K Alex Hodge; David S Alberts; Jose M Guillen-Rodriguez; Ting Dong; Maurizio Memo; Franco Odicino; Roberto Angioli; Lance A Liotta; Sergio L Pecorelli; Emanuel F Petricoin; Mariaelena Pierobon
Journal:  Br J Cancer       Date:  2017-06-29       Impact factor: 7.640

5.  Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy.

Authors:  Bolanle Gbadamosi; Daniel Ezekwudo; Bhadresh Nayak; Zhou Yu; Sandra Gjorgova-Gjeorgjievski; Ming Xie; Colvin Robert; Ishmael Jaiyesimi; Marianne Huben
Journal:  Case Reports Immunol       Date:  2018-02-12

6.  E2F1 germline copy number variations and melanoma susceptibility.

Authors:  Maria Santa Rocca; Clara Benna; Simone Mocellin; Carlo Riccardo Rossi; Aichi Msaki; Andrea Di Nisio; Giuseppe Opocher; Carlo Foresta
Journal:  J Transl Med       Date:  2019-05-29       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.